VTGN · Vistagen Therapeutics, Inc.
$0.24
+0.01 (+4.64%)
At close · Jul 29
Going-concern doubt
— flagged Jun 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of June 15, 2026, the issuance date of the consolidated financial statements as of and for the year ended March 31, 2026, there is uncertainty about whether the Company’s combined cash, cash equivalents, and marketable securities will be sufficient to fund operations beyond twelve months from the issuance date of these consolidated financial statements and therefore the Company concluded that substantial doubt existed about the Company’s ability to continue as a going concern.”View the 10-K filed Jun 15, 2026
Market Cap
$9.55M
Shares
41.03M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.23
Open$0.23
Day$0.22–0.24
52W$0.20–5.14
Avg vol 30d3.4M
Short int1.6M · 3.9% float · 1.0d
Short vol59%
Last earningsJun 30, 2026
DataJan 2020–Jul 2026
Filing10-K · Jun 15
Up next
Next earnings call
Oct 3, 2026
Est · unconfirmed
· in 9 wks
FQ2-27 quarter ends
~Sep 30, 2026
Est
filed Jun 15, 2026
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−84%
below
Price vs 50-day avg
−51%
below
RSI (14)
32
neutral
MACD trend
Positive
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−67%
trailing
6-month return
−60%
trailing
YTD return
−65%
this year
Relative strength
−67%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
4 of 57 funds reported for Jun 30 · net +47.6K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.89% of float · ▲ +0.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
57 holders — near 3-yr high, broad support
Squeeze score
32
low risk · 0–100
Fundamentals
Revenue growth
−120%
Y/Y
EPS growth
−10%
Y/Y
Free cash flow
$-66.6M
Balance sheet
$32.3M
net cash
Quant / Vol
risk profile
Volatility
132%
annualized · 1-yr
Max drawdown
−95%
past year
ATR
16.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−84%
Bearish
Price vs 50-day avg
−51%
Bearish
RSI (14)
32
Neutral
MACD trend
Positive
Bullish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
4 of 57 funds reported for Jun 30 · net +47.6K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.89% of float · ▲ +0.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
57 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $0
Now $0 · 1%
52-wk high $5
vs 200-day avg -84%
vs 50-day avg -51%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VTGN
this stock
Vistagen Therapeutics, Inc.
|
$9.55M | -64.7% | -120.5% | — | 3.9% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +8.8% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VTGN | +1.2% | -66.7% | -59.9% | +1.2% | -64.7% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | +2.2% | -66.7% | -67.3% | +2.0% | -73.4% |